Richter transformation of CLL

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Richter transformation (RT) is an aggressive transformation of chronic lymphocytic leukemia (CLL), typically into diffuse large B cell lymphoma (DLBCL).
• RT affects approximately 5% of CLL patients, representing a significant clinical challenge.
• Understanding the biology and treatment of RT is crucial for improving patient outcomes.

Purpose of the Study:

• This review focuses on the biology and treatment of Richter transformation (RT).
• It addresses the management of RT in the context of emerging targeted therapies.
• The review aims to identify key areas for future research and therapeutic development in RT.

Main Methods:

• The review synthesizes current literature on Richter transformation (RT) biology and treatment strategies.
• It categorizes RT into clonally-related and clonally-unrelated subtypes based on clonal relationship to CLL.
• Genetic aberrations, diagnostic modalities (PET scan, biopsy), and therapeutic approaches are discussed.

Main Results:

• Clonally-related RT is associated with a worse prognosis compared to clonally-unrelated RT, which resembles de novo DLBCL.
• Common genetic aberrations in RT include TP53, CDKN2A, MYC, and NOTCH1.
• Chemoimmunotherapy is the current standard treatment, but median survival is less than one year, indicating suboptimal outcomes.

Conclusions:

• Richter transformation (RT) remains a significant unmet medical need in hematologic oncology.
• Accurate diagnosis via biopsy and PET imaging is essential for appropriate management.
• Exploration of novel targeted therapies and immunotherapies is critical to improve survival for RT patients.